Triomics, an oncology AI company helping cancer centres operationalise complex clinical information, today announced it has raised $22 million in Series B financing.
The round was led by Battery Ventures, with participation from existing investors Nexus Venture Partners, Lightspeed and Y Combinator, alongside strategic backers Oncology Ventures and Precision Health Informatics, a wholly-owned subsidiary of Texas Oncology.
This round brings Triomics’ total funding raised to date to more than US$36 million.
The new capital will be used to accelerate adoption across health systems, oncology networks and life sciences organisations; grow Triomics’ AI/engineering and forward-deployed teams; and advance the company’s AI agents for clinical care and research.
“Oncology faces an information burden at a scale legacy systems were never designed to handle, and that burden can stand in the way of better outcomes,” said Sarim Khan, co-founder and CEO of Triomics.
“Clinicians, research coordinators and medical assistants are working against records that have become too large and too dynamic to process manually.
“We built Triomics to turn that complexity into usable intelligence inside the workflow, purpose-built for oncology.
“This financing allows us to bring that infrastructure to many more cancer centers and improve care for cancer patients.”
Founded in 2021 by Khan and Singh, Triomics is building a platform that uses AI agents to read the full longitudinal patient record and converts unstructured information into structured, explainable outputs.
Then, it delivers those insights directly into clinical and operational workflows.
Unlike lightweight summarisation tools, every output is source-backed and verifiable inside the clinician’s workflow.
The platform supports proactive clinical trial matching, pre-visit chart review and preparation, and oncology data abstraction for registry, quality improvement and operational use cases.
Cancer centres rely on Triomics to expand trial access, reduce the burden of manual chart review, improve visit preparation and generate higher‑quality structured data for research and operations.
Published results show that users of the company’s product have increased trial matches by 40 per cent and trial enrollments by more than 30 per cent, while also reducing chart review times by 67% per cent.
The platform has received peer-review validation in Nature Digital Medicine and was presented at ASCO, underscoring growing demand for AI that can operate reliably on the full patient record.
Lee Schwamm, MD is chief digital health officer, Yale New Haven Health System, and associate dean, Digital Strategy & Transformation, Yale School of Medicine.
Schwamm said: “We are excited to partner with Triomics, our selected solution for oncology clinical trial matching, to extend our collaboration to an AI-enabled method for cancer registry abstraction and reporting.
“This activity is labour intensive, subjective and challenging to complete in a timely manner.
“Our goal is to produce autonomous chart abstraction of clinical registry quality that can be rapidly reviewed and finalised for reporting by human registrars to comply with mandatory state, federal and professional society reporting obligations.”
Brandon Gleklen, principal at Battery Ventures, is joining the Triomics board of directors.
He said: “Triomics built what oncology has always needed: AI infrastructure that actually works on the full patient record.
We are live at some of the top cancer centres and demonstrating measurable outcomes—faster enrolment, less manual chart review—and the same underlying AI infrastructure already powers multiple distinct workflows with no redundant integrations.
“That kind of platform leverage, inside a customer base this strong, is rare at this stage.”
Startup secures US$4 million to analyse psychedelic therapy for veterans
